Cadrenal Therapeutics Inc. (CVKD) Live Share Price, Invest From India

Cadrenal Therapeutics Inc. Stock Performance

as on July 9, 2026 at 2:16 pm IST

Day's Low
Day's High
$3.00
Day's Price Range
$3.30
$3.10
3.23%
Downside
6.45%
Upside
52 Week's Low
52 Week's High
$2.55
52-Week Price Range
$14.64
$3.10
17.74%
Downside
372.26%
Upside

Cadrenal Therapeutics Inc. share price movements today

Previous Close: $3.16
Open: $3.08
Volume: 330.7K
Day's Low - High: $3.00 - $3.30
52 Week Low - High: $2.55 - $14.64

Cadrenal Therapeutics Inc. Historical Returns

1 Month Return: -21.52 %
3 Month Return: -37.63 %
1 Year Return: -76.1 %
3 Year Return: -86.31 %
5 Year Return: 0 %

Cadrenal Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Cadrenal Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$9.7M

EPS (TTM)

-7.74

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-12.0M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-300.59%

Cadrenal Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cadrenal Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Cadrenal Therapeutics Inc.	BUY	$9.7M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$42.9B	83.04%	80.6	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$132.5B	151.53%	31.44	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$70.9B	14.21%	15.87	29.65%	0.5499999999999999%

Stock Returns calculator for Cadrenal Therapeutics Inc. Stock including INR - Dollar returns

The Cadrenal Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Cadrenal Therapeutics Inc. investment value today

Current value as on today

₹26,631

Returns

-₹73,369

(-73.37%)

Returns from Cadrenal Therapeutics Inc. Stock

-₹76,099 (-76.1%)

Dollar Impact

₹2,730 (+2.73%)

Analyst Recommendation on Cadrenal Therapeutics Inc. Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Cadrenal Therapeutics Inc.. Average target price of $27.67

Cadrenal Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Cadrenal Therapeutics Inc..

What analysts predicted

88.8%UPSIDE

Target Price

$27.67

Current Price

$3.1

Analyzed by

8 Analysts

Target

$27.67

Cadrenal Therapeutics Inc. target price $27.67, a slight upside of 88.8% compared to current price of $3.1. According to 8 analysts rating.

Indian Investors' Interest in Cadrenal Therapeutics Inc. Stock

Search interest for Cadrenal Therapeutics Inc. Stock has increased by 44% in the last 30 days, reflecting an upward trend in search activity.

Time period: June 9, 2026 to July 9, 2026

Change:44% versus previous 30 day period

Cadrenal Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	0	-	-	-	0	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-1	-1	-2	-2	-4	-3	-3	-2	-3	-2
EBITDA	-1	-1	-2	-2	-4	-3	-3	-2	-3	-2
Interest Expense	0	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-1	-1	-2	-2	-4	-3	-3	-2	-3	-2
Income Tax Expense	0	0	-	-	-	-	-	-	-	-
Net Income	-1	-1	-2	-2	-4	-3	-3	-2	-3	-2
Net Profit Margin	-41331.65%	0.00%	0.00%	0.00%	-196216.92%	0.00%	0.00%	0.00%	0.00%	0.00%

Cadrenal Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-
Gross Profit	0	0	-
Operating Income	-7	-10	-13
EBITDA	-8	-10	-13
Interest Expense	0	-	-
Depreciation	0	0	0
Income Before Tax	-8	-10	-13
Income Tax Expense	0	-	-
Net Income	-8	-10	-13
Net Profit Margin	0.00%	0.00%	0.00%

Cadrenal Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-1	-2	-2	-4	-3	-3	-2	-3	-2
Operating Cash Flow	-1	-1	-2	-1	-4	-3	-2	-2	-3
Investing Cash Flow	-	-	-	0	0	0	0	0	-
Financing Cash Flow	0	-	1	7	1	1	0	2	1
Change in Cash	-1	-1	0	5	-2	-1	-1	0	-1

Cadrenal Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Net Income	-8	-10	-13
Operating Cash Flow	-3	-7	-12
Investing Cash Flow	0	0	0
Financing Cash Flow	11	8	6
Change in Cash	8	1	-6

Global Institutional Holdings in Cadrenal Therapeutics Inc.

Funds	Holdings
Geode Capital Management, LLC	0.7%
Cygnus Capital Advisors, LLC	0.05%
JONES FINANCIAL COMPANIES LLLP	0%
Hartland & Co	0%
CURIO WEALTH, LLC	0%

See all

Insights on Cadrenal Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 20.0% return, outperforming this stock by 96.1%
NO EFFECT
Against Peers
In the last 3 years, Cadrenal Therapeutics, Inc. Common Stock has experienced a drawdown of -86.3%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 82.0%
NEGATIVE IMPACT
Price Dip
In the last 7 days, CVKD stock has moved down by -13.9%

About Cadrenal Therapeutics Inc.

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Organisation	Cadrenal Therapeutics Inc.
Headquarters	822 A1A North, Ponte Vedra, FL, United States, 32082
Industry	Biotechnology
CEO	Mr. Quang X. Pham
E-voting on shares	Click here to vote

Key Management of Cadrenal Therapeutics Inc.

Name	Title
Mr. Quang X. Pham	Chairman, CEO, Interim CFO & Interim Principal Accounting Officer
Dr. James J. Ferguson FACC, M.D.	Chief Medical Officer
Mr. Jeffrey Cole	Chief Operating Officer
Dr. Matthew Boxer M.B.A., Ph.D.	Executive Vice President of Corporate Development

FAQs

What is Cadrenal Therapeutics Inc. share price today?

Cadrenal Therapeutics Inc. share price today is $3.10 as on July 9, 2026 at 8:46 am IST at the close of the market. Cadrenal Therapeutics Inc. share today touched a day high of $3.30 and a low of $3.00.

What is the 52 week high and 52 week low for Cadrenal Therapeutics Inc. share?

Cadrenal Therapeutics Inc. share touched a 52 week high of $14.64 on September 25, 2025 and a 52 week low of $2.55 on June 24, 2026. Cadrenal Therapeutics Inc. stock price today i.e. July 9, 2026 at 8:46 am IST is closed at $3.10,which is 78.83% down from its 52 week high and 21.57% up from its 52 week low.

What is Cadrenal Therapeutics Inc.'s market capitalisation today?

Cadrenal Therapeutics Inc. market capitalisation is $0.00T as on July 9, 2026 at 8:46 am IST.

How to invest in Cadrenal Therapeutics Inc. Stock (CVKD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cadrenal Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cadrenal Therapeutics Inc. Shares that will get you 0.4839 shares as per Cadrenal Therapeutics Inc. share price of $3.10 per share as on July 9, 2026 at 8:46 am IST.

What is the minimum amount required to buy Cadrenal Therapeutics Inc. Stock (CVKD) from India?

Indian investors can start investing in Cadrenal Therapeutics Inc. (CVKD) shares with as little as ₹95.555 or $1 (as of July 9, 2026 at 2:37 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹955.55 in Cadrenal Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on July 9, 2026 at 2:37 pm IST). Based on Cadrenal Therapeutics Inc. share’s latest price of $3.10 as on July 9, 2026 at 8:46 am IST, you will get 3.2258 shares of Cadrenal Therapeutics Inc.. Learn more about fractional shares .